Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Randomized, Double-Blind Study Evaluating ALKS 2680 Tablets for Treating Narcolepsy Type 1 in Adults
Researchers are investigating the effects of ALKS 2680 tablets on adults with Narcolepsy Type 1 NT1. The study aims to measure reductions in daytime sleepiness, cataplexy sudden loss of muscle tone, and overall disease symptoms. This is a Phase 3, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of ALKS 2680 compared with placebo. Participants will be randomly assigned to receive one of two doses of ALKS 2680 tablets or placebo tablets. All treatments are taken orally once daily for 12 weeks. The study employs a parallel design with triple masking to compare the effects of the two doses of ALKS 2680 against placebo over the treatment period. During the 12-week treatment, participants will undergo various assessments including the Maintenance of Wakefulness Test to measure sleep latency, Epworth Sleepiness Scale, cataplexy rate tracking, and cognitive and fatigue questionnaires. Researchers will also monitor treatment-emergent adverse events up to two weeks after treatment ends. The total participation duration includes treatment and follow-up assessments to evaluate treatment impact and safety.
Actively Recruiting
Researchers are collecting detailed data about suicide attempts and suicidal thoughts among people who come to healthcare services in Flanders. The study aims to understand how often these behaviors occur, the methods used, and how many receive proper follow-up care after a suicide attempt. This observational study uses a structured interview tool called the Guideline for Suicide Care and Evaluation LOES to gather comprehensive information. Participants undergo a two-part semi-structured interview administered by trained nurses, psychologists, or psychiatrists. The first part happens soon after admission to a healthcare facility and collects information on emotional state, mental health history, social support, hopelessness, and suicidal behavior. The second part provides a deeper evaluation of risk factors, treatment needs, motivations, planning, and coping strategies related to suicidality. Throughout the study, participants provide demographic, clinical, and psychological information through interviews. Researchers assess suicidal intent, planning, past behavior, substance use risk, and care needs. The study tracks treatment agreements and care pathways after assessment. Data collection occurs at the initial presentation, with no drug or medical treatment being tested. The total participation time varies depending on the individuals healthcare encounters and follow-up.